Navigation Links
'Obscurins' in breast tissue may help physicians predict and detect breast cancer
Date:3/21/2012

Bethesda, MDA new discovery published online in The FASEB Journal (http://www.fasebj.org) may lead to a new tool to help physicians assess breast cancer risk as well as diagnose the disease. In the report, researchers from Johns Hopkins University and the University of Maryland, explain how proteins, called "obscurins," once believed to only be in muscle cells, act as "tumor suppressor genes" in the breast. When their expression is lost, or their genes mutated in epithelial cells of the breast, cancer develops. It promises to tell physicians how breast cancer develops and/or how likely it is.

"Our studies on the role of obscurins in the development of breast cancer lay the framework for a series of in-depth investigations aiming to understand how these proteins act to prevent tumor formation," said Aikaterini Kontrogianni-Konstantopoulos, Ph.D., a researcher involved in the work from the Department of Biochemistry and Molecular Biology at the University of Maryland School of Medicine in Baltimore, MD. "It is our hope that our research will provide important new insights into breast tumor biology and ultimately yield new targets for the development of innovative therapeutic strategies."

To make this discovery, Kontrogianni-Konstantopoulos and colleagues used a highly specific antibody probe to detect obscurins in normal and cancerous breast, skin, and colon cells. They observed that cancer cells expressed significantly lower amounts of obscurins compared to normal cells, leading to the hypothesis that loss of obscurins allowed normal cells to become cancerous. The researchers then compared two breast epithelial cell populations: a "normal" one, which expressed obscurins and served as a control, and an "altered" one, which failed to express obscurins through genetic manipulations. Both cell populations were treated with a chemical called "etoposide," which causes massive DNA damage and induces cell death. Scientists detected and quantified cell death with a number of different methodologies, and found that etoposide caused a significantly high percentage of cell death in normal cells, but only a very low percentage of cell death in the altered, obscurin-deficient cells. This suggests that the loss of obscurins makes breast epithelial cells more resistant to the natural cell death necessary to prevent damaged cells from transforming into a run-away cancer.

"This study is important for a number of reasons. First, it shows that there is a lot more to obscurins than previously thought, making future research into this family of proteins important. Second, it reveals a previously unknown group of tumor suppressors in the breast that prevent normal cells from becoming cancerous. Finally, it opens doors to new tools to help doctors assess a person's risk for cancer and possibly to diagnose it in the earliest of stages," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal.


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
(Date:6/23/2016)... June 23, 2016  Experian Health, the ... transforming the patient payment and care experience, ... new products and services that will enhance ... cycle offerings. These award-winning solutions will enable ... remain compliant in an ever-changing environment and ...
Breaking Medicine Technology: